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Editorial Comment 
Intracranial Hemorrhage After 
Thrombolytic Therapy: 
A Therapeutic Conflict* 
JOSEPH S. ALPERT, MD, FACC 
Worcester, Massachusetts 
For extreme illnesses, extreme treatments are most fitting. 
Hippocrates, Aphorisms. 1.6 
As to diseases, make a habit of two things-to help, or at 
least do no harm. 
Hippocrates, Epidemics. Bk. I, Sect. XI 
These two Hippocratic statements are well known to most 
physicians. The first is often cited when the physician 
prepares for an aggressive intervention against a lethal 
disease and the second when drugs or procedures are 
associated with iatrogenic complications. These two pieces 
of Hippocratic advice conflict when discussing thrombolytic 
therapy for acute myocardial infarction. On the one hand, 
aggressive interventional therapy, including intravenous 
thrombolytic agents, has been repeatedly associated with 
decreased in-hospital and long-term mortality after acute 
infarction. On the other hand, controlled trials and clinical 
experience have clearly documented hemorrhagic deaths 
secondary to thrombolytic therapy itself. Many of these 
iatrogenic deaths are the result of intracranial hemorrhage. 
The present study. In most of the carefully controlled, 
randomized trials of thrombolytic therapy, the incidence of 
intracranial hemorrhage has been low (0.3% to 0.6%), al-
though a frequency of up to 1.6% has been reported (1-5). In 
this issue of the Journal, De Jaegere and coworkers (6) 
report a high rate of intracranial hemorrhage (1%) in a 
registry of 2,469 patients with acute myocardial infarction 
admitted to 61 hospitals in the Netherlands. The clear 
implication of this study is that registry patients are at higher 
risk for intracranial hemorrhage compared with the highly 
selected population of the randomized controlled trials. 
Since the Dutch registry patients probably resemble non-
study patients in the United States, one anticipates that rates 
of intracranial hemorrhage will also be higher in patients 
with "routine" infarction treated with thrombolytic agents 
in the United States. 
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As in all such studies, a number of questions can be raised 
concerning the study of De Jaegere et al. (6). What clinical 
criteria were used to make the diagnosis of intracranial 
hemorrhage? Most but not all patients with this diagnosis 
had a computed tomographic (CT) scan of the brain. How 
was the presence of intracranial hemorrhage determined in 
patients who did not undergo CT scanning? How were 
registry data validated and standardized among the 61 insti-
tutions? What were the dose and route of administration 
when heparin was given? These and many other questions 
will need to be answered in future communications from this 
registry and others monitoring thrombolytic therapy. Even-
tually, some of these issues will need to be addressed in 
more formal clinical trials. The importance of these ques-
tions is clear, because higher rates of intracranial hemor-
rhage with attendant increased mortality may alter assess-
ments of risk/benefit ratio in managing patients with acute 
myocardial infarction. 
Predicting increased risk of intracranial hemorrhage. 
Given the very high mortality rate associated with intracra-
nial hemorrhage, cardiologists are anxiously seeking strate-
gies to prevent or at least decrease the risk of its occurrence. 
Several clinical factors have been associated with intracra-
nial hemorrhage (Table 1) (5-7). This does not mean that 
these factors necessarily cause intracranial hemorrhage; 
they are merely associated with an increased risk of its 
occurrence. 
Many clinicians avoid using thrombolytic agents in the 
presence of these risk factors. In so doing, they may be 
rendering a disservice to their patients because the increased 
risk of dying from acute myocardial infarction treated con-
ventionally may far outweigh the risk of intracranial hemor-
rhage. Clearly, more data from registries and controlled 
trials are required to construct a complete picture of throm-
bolytic therapy risk/benefit ratio in the presence of risk 
factors for intracranial hemorrhage. 
An American patient with an acute myocardial infarction 
is approximately one-third to one-half as likely as his or her 
Table 1. Factors Associated With Increased Risk of 
Intracranial Hemorrhage 
Factors associated with increased risk in one study 
Use of anticoagulant drugs on admission* 
Diabetes mellitus 
Female gender* 
rt-PA dose 150 mg vs. 100 mg* 
Calcium channel blocker therapy on admission 
Factors associated with increased risk in more than one study 
Older age (>65 years)* 
Low body weight ( <70 kg)* 
Hypertension on admission* 
Cerebrovascular disease by history 
*Multivariate analysis confirmed these factors to be independent predic-
tors of intracranial hemorrhage. 
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European counterpart to receive thrombolytic therapy 
(Goldberg RJ. Unpublished observations from the Worces-
ter Heart Attack Study, 1986-1990). Thus, our European 
cardiology colleagues do not assess risk/benefit ratio associ-
ated with thrombolytic therapy in the same manner that we 
do. This disparity needs to be examined closely: are we 
treating too few patients or are they treating too many? My 
own prejudice lies with the former assertion. 
Conclusions. We know that thrombolytic therapy de-
creases mortality associated with acute myocardial infarc-
tion but at an increased risk for intracranial hemorrhage. A 
variety of clinical factors are associated with this increased 
risk, although the benefits of thrombolytic therapy may 
outweigh this risk. These associations and the affiliated 
risk/benefit ratio require intense scrutiny in the future. Like 
so many important clinical questions in the past: 
All our knowledge brings us nearer to our ignorance, 
All our ignorance brings us nearer to death. 
T.S. Eliot, "The Rock" 
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